PriceTargets.com logo

Pro Medicus - PMCUF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $54.00
  • Forecasted Upside: 43.85 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$37.54 As of 08/17/2022 01:00 AM ET
▼ -0.6 (-1.57%)

This chart shows the closing price for PMCUF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pro Medicus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PMCUF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PMCUF

Analyst Price Target is $54.00
▲ +43.85% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pro Medicus in the last 3 months. The average price target is $54.00, with a high forecast of $54.00 and a low forecast of $54.00. The average price target represents a 43.85% upside from the last price of $37.54.

This chart shows the closing price for PMCUF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Pro Medicus. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/22/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
7/7/2022The Goldman Sachs GroupUpgradeSell ➝ Neutral
11/9/2021CitigroupInitiated CoverageSell
9/3/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$54.00
7/30/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral
2/17/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
1/13/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
8/21/2020UBS GroupUpgradeNeutral ➝ Buy
6/25/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
5/29/2019The Goldman Sachs GroupInitiated CoverageNeutral
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/20/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Pro Medicus logo
Pro Medicus Limited develops and supplies healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. It provides Radiology Information Systems (RIS) proprietary medical software for practice management. The company also offers Healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; Promedicus.net., an e-health platform; and integration products. In addition, it offers Visage Ease Pro, a mobile application, which allow users to interpret medical imaging studies that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Read More

Today's Range

Now: $37.54
Low: $37.54
High: $37.54

50 Day Range

MA: $31.98
Low: $26.26
High: $38.14

52 Week Range

Now: $37.54
Low: $26.26
High: $48.81

Volume

300 shs

Average Volume

963 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pro Medicus?

The following sell-side analysts have issued stock ratings on Pro Medicus in the last year: Citigroup Inc., Royal Bank of Canada, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for PMCUF.

What is the current price target for Pro Medicus?

1 Wall Street analysts have set twelve-month price targets for Pro Medicus in the last year. Their average twelve-month price target is $54.00, suggesting a possible upside of 43.8%. The Goldman Sachs Group, Inc. has the highest price target set, predicting PMCUF will reach $54.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $54.00 for Pro Medicus in the next year.
View the latest price targets for PMCUF.

What is the current consensus analyst rating for Pro Medicus?

Pro Medicus currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PMCUF, but not buy more shares or sell existing shares.
View the latest ratings for PMCUF.

What other companies compete with Pro Medicus?

Other companies that are similar to Pro Medicus include eWellness Healthcare, Lynx Global Digital Finance, (UPGI), 01 Communique Laboratory and 1mage Software. Learn More about companies similar to Pro Medicus.

How do I contact Pro Medicus' investor relations team?

Pro Medicus' physical mailing address is 450 Swan Street, Richmond, Victoria (VIC). The company's listed phone number is 61 3 9429 8800. The official website for Pro Medicus is www.promed.com.au. Learn More about contacing Pro Medicus investor relations.